Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: Report of seven cases

American Journal of Medicine

Volumn 107, Issue 6, 1999, Pages 624-626

  George, Sarah L ^a   Swindells, Susan ^b   Knudson, Ralph ^c   Stapleton, Jack T ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c Family Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; WARFARIN; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCOAGULABILITY; LUNG EMBOLISM; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK;

ADULT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NELFINAVIR; RISK FACTORS; RITONAVIR; SAQUINAVIR; VENOUS THROMBOSIS;

EID: 0032796286     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00296-X     Document Type: Article

References (19)

1. Powderly W.G., Landay A., Lederman M.M. Recovery of the immune system with antiretroviral therapy the end of opportunism? JAMA. 280:1998;72-77.
2. Hemophilia Information Exchange. HIV Protease Inhibitors and Patients with Hemophilia. Medical Bulletin #250, Chapter Advisory #252. National Hemophilia Foundation, New York City, New York, July 17, 1996.
3. CDC report on bleeding complications observed among persons with hemophilia treated with protease inhibitors. United States Public Health Service Centers for Disease Control, Atlanta, Georgia, January 1997.
4. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy (LD), hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12:1998;F51-F58.
5. Henry K., Melroe H., Huebesch J., et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet. 352:1998;1031-1032.
6. Henry K., Melroe H., Huebsch J., et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 351:1998;1328.
7. Behrens G, Schmidt H, Meyer D, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1958. Letter.
8. Gallet B, Pulik M, Genet P, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1958-1959. Letter.
9. Carr A., Brown D., Cooper D.A. Portal vein thrombosis in patients receiving indinavir, an HIV protease inhibitor. AIDS. 11:1997;1657-1658.
10. Pulik M., Lionnet F., Couderc L.J., et al. Thromboembolic disease and human immunodeficiency virus infection. Blood. 82:1993;2931.
11. Pulik M., Lefebvre d'Hellencourt S., Couderc L.J., et al. Unexplained venous thrombosis in HIV-infected patients. International Conference on AIDS, June 20-23. 1990;abstract #2038.
12. Lewis B., Brosgart C., Bresnik M., Jacobson S. Venous thromboembolic disease in AIDS. International Conference on AIDS, June 20-23. 1990;abstract #FB 506.
13. Toulon P., Frere E., Bachmeyer C., et al. Fibrin polymerization defect in HIV-infected patients - evidence for a critical role of albumin in the prolongation of thrombin and reptilase clotting times. Thrombos Hemostas. 73:1995;349-355.
14. Meyohas M.C., Roullet E., Rouzioux C., et al. Cerebral venous thrombosis and dual primary infection with HIV and CMV. J Neurol Neurosurg Psychiatry. 52:1989;1010-1011.
15. Smith KJ, Skelton HG, Yeager J, Wagner KF. Cutaneous thrombosis in HIV-1 positive patients and cytomegalovirus viremia. Arch Dermatol 1995;131:357-358. Letter.
16. Karmochkine M., Ankri A., Calvez V., et al. Plasma hypercoagulability is correlated to plasma HIV load. Thrombos Hemostas. 80:1998;208-209.
17. Feffer S.E., Fox R.I., Orsen M.M., et al. Thrombotic tendencies and correlation with clinical status in patients infected with HIV. South Med J. 88:1995;1126-1130.
18. Pulik M., Jary L., Genet P., et al. Coagulation studies in non-hemophiliac HIV-infected patients treated with protease inhibitors. Fourth Conference on Retroviruses and Opportunistic Infections, January 22-26. 1997;abstract no. 201.
19. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet. 131:1998;1881-1883.